Indications
Treatment of patients with pulmonary arterial hypertension (PAH) classified as WHO functional class III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and in pulmonary hypertension associated with connective tissue disease.
Composition
- Active substance
- sitaxentan sodium
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Thelin
- Active substance
- sitaxentan sodium
- ATC code
- C02KX03
- Therapeutic area
- Hypertension, Pulmonary
- Marketing authorisation holder
- Pfizer Ltd.
- Status
- Withdrawn